2025.0425
[News] Publication of Review Result of the 2nd Pharmaceutical Reimbursement Evaluation Committee of 2025
Publication of Review Result of the 2nd Pharmaceutical Reimbursement
Evaluation Committee of 2025
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the results of the deliberations of the 2nd Pharmaceutical Reimbursement Evaluation Committee in 2025 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
Product
Pharmaceutical company
Efficacy and effectiveness
Deliberation results
Adempas Tab. 0.5mg, 1mg, 2mg, 2.5mg (Riociguat)
Bayer Korea
1. pulmonary arterial hypertension
2. chronic thromboembolic pulmonary hypertension
Reimbursement is adequate
(1. Pulmonary hypertension)
Bimzelx Autoinjector
(Bimekizumab)
UCB Korea
plaque psoriasis
Reimbursement is adequate when accepted at or below assessed value
Ebglyss Autoinjector inj(Lebrikizumab, genetic recombination)
Eli Lilly and
Company Korea
atopic dermatitis
Reimbursement is adequate when accepted at or below assessed value
Trodelbi Inj
(Sacituzumabgovitecan)
Gilead Sciences Korea
Triple Negative Breast Cancer
Reimbursement is adequate
- HIRA accepted benefit quality of Trodelvy inj., an anticancer drug in favor of a patient who contracts triple negative breast cancer (TNBC).
This acceptance comes as the first case of HIRA’s system improvement process in pursuit of ensuring patients’ enhanced accessibility for a new drug which was recognized as innovative.
○ Evaluation results of the expanded scope of use for risk-sharing agreement pharmaceutical
Product
Pharmaceutical company
Efficacy and effectiveness
Deliberation results
Cabometyx Tab. 20, 40, 60mg
(Cabozantinib)
Ipsen Korea
Clear cell renal cell carcinoma(ccRCC)
Reimbursement is adequate when accepted at or below assessed value
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval.
